GENB
GENB clinical trials: Generate Biomedicines, Inc.
Every trial on ClinicalTrials.gov where Generate Biomedicines, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 6
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
GENB on the catalyst calendar · GENB registry changes
- Primary completion Jan 2029Sponsor estimatePhase 3NCT07359846A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)Generate Biomedicines · Severe AsthmaRecruitingGENBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 3NCT07276724A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)Generate Biomedicines · Severe AsthmaRecruitingGENBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1NCT07484022Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerGenerate Biomedicines · Advanced Urothelial CancerRecruitingGENBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2026Sponsor estimatePhase 1NCT06920693Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult ParticipantsGenerate Biomedicines · Atopic Dermatitis (AD)Active, not recruitingGENBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 1NCT07116889A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPDGenerate Biomedicines · AsthmaActive, not recruitingGENBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 22, 2024ActualPhase 1NCT07050511Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult ParticipantsGenerate Biomedicines · SARS CoV-2CompletedGENBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 18, 2028Sponsor estimatePhase 1NCT07489287GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube CancerRoswell Park Cancer Institute · Platinum-resistant Ovarian CancerRecruitingGENBCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner